CXCR4
Overview
CXCR4 is one of a number of genes affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. No notable hot spots have been described in this gene in the context of the cancers listed below. The mutation pattern in DLBCL implies the preferential accumulation of inactivating mutations.
History
Mutations in this gene were first described in DLBCL in 2012 by Khodabakhshi et al,1 in FL in 2021 by Hübschmann et al2 and in BL in 2019 by Panea et al.3
The variants reported in this gene in BL failed QC
%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
timeline
title Publication timing
2012-11-12 : Khodabakhshi : DLBCL
2017-01-26 : Krysiak : FL
2019-09-26 : Panea : BL
Relevance tier by entity
| Entity | Tier | Description |
|---|---|---|
| 1 | high-confidence MZL gene | |
| 1-a | aSHM target and high-confidence DLBCL gene1 | |
| 2-a | aSHM target; Although recurrent, the relevance of mutations in FL is tenuouskrysiakRecurrentSomaticMutations2017b? | |
| 2-a | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous2 |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
| Entity | source | frequency (%) |
|---|---|---|
| BL | GAMBL genomes+capture | 2.08 |
| BL | Thomas cohort | 2.10 |
| BL | Panea cohort | 2.00 |
| DLBCL | GAMBL genomes | 2.87 |
| DLBCL | Schmitz cohort | 2.55 |
| DLBCL | Reddy cohort | 1.50 |
| DLBCL | Chapuy cohort | 2.56 |
| FL | GAMBL genomes | 3.46 |
Mutation pattern and selective pressure estimates
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | Yes | No | 4.603 | 0.000 |
| DLBCL | Yes | No | 3.731 | 18.727 |
| FL | Yes | No | 0.000 | 0.000 |
aSHM regions
| chr_name | hg19_start | hg19_end | region | regulatory_comment |
|---|---|---|---|---|
| chr2 | 136874728 | 136875461 | intron | weak_promoter |
View coding variants in ProteinPaint hg19 or hg38
View all variants in GenomePaint hg19 or hg38
CXCR4 Expression
Representative Mutations
BL
Rating ★ ★ ★ ★ ★
References
1.
Khodabakhshi AH, Morin RD, Fejes AP, Mungall
AJ, Mungall KL, Bolger-Munro M, Johnson NA, Connors JM, Gascoyne RD,
Marra MA, Birol I, Jones SJM. Recurrent targets of aberrant somatic
hypermutation in lymphoma. Oncotarget. 2012;3(11):1308–1319. PMCID: PMC3717795
2.
Panea R, Love C, Shingleton JR, Reddy A, Bailey
J, Moormann A, Otieno J, Ong’echa J, Oduor C, Schroêder K, Masalu N,
Chao N, Agajanian M, Major M, Fedoriw Y, Richards K, Rymkiewicz G, Miles
R, Alobeid B, Bhagat G, Flowers C, Ondrejka S, Hsi E, Choi W, Au-Yeung
R, Hartmann W, Lenz G, Meyerson H, Lin YY, Zhuang Y, Luftig M, Waldrop
A, Dave T, Thakkar D, Sahay H, Li G, Palus B, Seshadri V, Kim S,
Gascoyne R, Levy S, Mukhopadhyay M, Dunson D, Dave S. The whole genome
landscape of Burkitt lymphoma subtypes. Blood. 2019;


